Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more
Oncopeptides AB (ONCO) - Net Assets
Latest net assets as of September 2025: Skr6.54 Million SEK
Based on the latest financial reports, Oncopeptides AB (ONCO) has net assets worth Skr6.54 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr211.28 Million) and total liabilities (Skr204.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.54 Million |
| % of Total Assets | 3.09% |
| Annual Growth Rate | 21.71% |
| 5-Year Change | -90.59% |
| 10-Year Change | N/A |
| Growth Volatility | 479.07 |
Oncopeptides AB - Net Assets Trend (2014–2024)
This chart illustrates how Oncopeptides AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncopeptides AB (2014–2024)
The table below shows the annual net assets of Oncopeptides AB from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr54.28 Million | -4.39% |
| 2023-12-31 | Skr56.78 Million | -80.71% |
| 2022-12-31 | Skr294.29 Million | +39.56% |
| 2021-12-31 | Skr210.87 Million | -63.45% |
| 2020-12-31 | Skr576.90 Million | -27.62% |
| 2019-12-31 | Skr797.01 Million | +152.35% |
| 2018-12-31 | Skr315.83 Million | -24.44% |
| 2017-12-31 | Skr418.00 Million | +1487.15% |
| 2016-12-31 | Skr26.34 Million | +1112.95% |
| 2015-12-31 | Skr-2.60 Million | -134.19% |
| 2014-12-31 | Skr7.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncopeptides AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 552353030500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr23.91 Million | 44.05% |
| Other Comprehensive Income | Skr-2.84 Million | -5.24% |
| Other Components | Skr5.68 Billion | 10470.32% |
| Total Equity | Skr54.28 Million | 100.00% |
Oncopeptides AB Competitors by Market Cap
The table below lists competitors of Oncopeptides AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Schloss Wachenheim AG
F:SWA
|
$34.55 Million |
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
$34.55 Million |
|
SDI Ltd
AU:SDI
|
$34.55 Million |
|
Gogoro Inc
NASDAQ:GGR
|
$34.55 Million |
|
Cuprum
SN:CUPRUM
|
$34.54 Million |
|
Shihlin Development Company Limited
TWO:5324
|
$34.54 Million |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
$34.53 Million |
|
PharmGen Science Inc
KO:004720
|
$34.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncopeptides AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 56,780,000 to 54,285,000, a change of -2,495,000 (-4.4%).
- Net loss of 284,607,000 reduced equity.
- Share repurchases of 313,483,000 reduced equity.
- New share issuances of 313,483,000 increased equity.
- Other comprehensive income decreased equity by 644,000.
- Other factors increased equity by 282,756,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-284.61 Million | -524.28% |
| Share Repurchases | Skr313.48 Million | -577.48% |
| Share Issuances | Skr313.48 Million | +577.48% |
| Other Comprehensive Income | Skr-644.00K | -1.19% |
| Other Changes | Skr282.76 Million | +520.87% |
| Total Change | Skr- | -4.39% |
Book Value vs Market Value Analysis
This analysis compares Oncopeptides AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.64x to 5.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.20 | Skr1.69 | x |
| 2015-12-31 | Skr-0.07 | Skr1.69 | x |
| 2016-12-31 | Skr0.68 | Skr1.69 | x |
| 2017-12-31 | Skr10.78 | Skr1.69 | x |
| 2018-12-31 | Skr7.36 | Skr1.69 | x |
| 2019-12-31 | Skr15.42 | Skr1.69 | x |
| 2020-12-31 | Skr9.25 | Skr1.69 | x |
| 2021-12-31 | Skr2.80 | Skr1.69 | x |
| 2022-12-31 | Skr3.57 | Skr1.69 | x |
| 2023-12-31 | Skr0.45 | Skr1.69 | x |
| 2024-12-31 | Skr0.33 | Skr1.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncopeptides AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -524.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -899.29%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 4.50x
- Recent ROE (-524.28%) is below the historical average (-289.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -435.13% | 0.00% | 0.00x | 1.73x | Skr-33.85 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-53.08 Million |
| 2016 | -434.55% | 0.00% | 0.00x | 2.11x | Skr-117.08 Million |
| 2017 | -59.24% | 0.00% | 0.00x | 1.15x | Skr-289.42 Million |
| 2018 | -132.81% | 0.00% | 0.00x | 1.41x | Skr-451.03 Million |
| 2019 | -92.94% | 0.00% | 0.00x | 1.25x | Skr-820.41 Million |
| 2020 | -276.43% | -8239.18% | 0.02x | 1.64x | Skr-1.65 Billion |
| 2021 | -678.30% | -1209.11% | 0.27x | 2.08x | Skr-1.45 Billion |
| 2022 | -114.83% | -4044.90% | 0.02x | 1.31x | Skr-367.38 Million |
| 2023 | -438.73% | -707.30% | 0.15x | 4.20x | Skr-254.79 Million |
| 2024 | -524.28% | -899.29% | 0.13x | 4.50x | Skr-290.04 Million |
Industry Comparison
This section compares Oncopeptides AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncopeptides AB (ONCO) | Skr6.54 Million | -435.13% | 31.32x | $34.55 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |